Clinical trial
Anti-Cytokine Therapy for Hemodialysis InflammatION (ACTION): A Phase II Multi-center Study to Evaluate the Safety and Tolerability of Anakinra, an IL-1 Receptor Antagonist, for Patients Treated With Maintenance Hemodialysis
NCT03141983 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Anti-Cytokine Therapy for Hemodialysis InflammatION (ACTION): A Phase II Multi-center Study to Evaluate the Safety and Tolerability of Anakinra, an IL-1 Receptor Antagonist, for Patients Treated With Maintenance Hemodialysis
- Lead sponsor
- University of Pennsylvania
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 15, 2017
- Completion date
- September 2, 2021
- Enrollment
- 80 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
end-stage renal disease